Precision-engineered conjugation for antibodies and nanobodies using cysteine re-bridging, enzymatic ligation, and glycan or click chemistries. Achieve homogeneous conjugates, controlled DAR, and LC-MS verified quality under ISO-certified systems.
Bio-Synthesis conjugation services provide advanced site-specific platform enables homogeneous antibody-drug conjugates (ADCs) and nanobody-fluorophore conjugates through bioorthogonal click and enzymatic Sortase A labeling. We combine bis-maleimide re-bridging, enzymatic ligation, glycan-directed oxime/hydrazone, and click chemistry (DBCO↔Azide, TCO↔Tetrazine) to build homogeneous conjugates for ADC prototypes, imaging probes, and nanobody-drug conjugates.
Our linker portfolio (pyridazinedione, dibromomaleimide, Sortase A, TGase, FGE) is verified by LC-MS, HIC, and SEC-MALS under ISO 9001/13485 workflows—improving stability, pharmacokinetics, and reproducibility from discovery to preclinical scale.
Learn more about our antibody conjugation expertise or payload and label conjugation capabilities.
✓ Compatible | △ Conditional (buffer or sequence dependent) | ✗ Avoid
Tell us about your biomolecule, desired label/payload, and intended use. We’ll recommend chemistry, linker design, and release testing to meet your goals.
By submitting, you agree to be contacted regarding your request.
Have a publication citing Bio-Synthesis conjugation? Contact us to be featured here.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.